Severity

Government of Canada helps Jewish community in Montréal protect itself against hate-motivated crimes

Retrieved on: 
Thursday, March 14, 2024
Parliament, Federation CJA, Public security, Freedom, Face, Environment, Severity, Federation, Risk, Education, Child, Fear, Public, Organization, Student, Expansion, Obligatory Baháʼí prayers, Human back, Safety, Lighting, Treasury Board of Canada, Parent, MADA, Private investigator

The Government of Canada is committed to helping Canadian communities at risk of hate-motivated crimes to protect themselves.

Key Points: 
  • The Government of Canada is committed to helping Canadian communities at risk of hate-motivated crimes to protect themselves.
  • This program is more vital today than ever before, not only for the Jewish community but for other communities in Canada as well."
  • Given the recent targeting of Jewish institutions and record antisemitism; government investments are essential in securing our institutions."
  • Since the inception of the Security Infrastructure Program, the Government of Canada has invested over $14 million through the program to support over 600 projects for communities at risk of hate-motivated crimes.

VESA Announces DisplayPort Updates and Extensions for Gaming and Automotive Market at CES

Retrieved on: 
Monday, January 8, 2024
Car, Automotive Safety Integrity Level, The Palazzo, Controllability, CRC, Consumer Electronics Show, Severity, VIP, Metadata, Electronics, VESA, DisplayPort, GPU, Behavior, DSC, Data-rate units, Noise, Display Stream Compression, ISO, MST, Silicon, Safety, CES, EDP, ASIL, Embedded, Video game

BEAVERTON, Ore., Jan. 8, 2024 /PRNewswire/ -- The Video Electronics Standards Association (VESA®) today announced that it has published the latest update to DisplayPort, version 2.1a. This update replaces the VESA certified DP40 ultra-high-bit-rate (UHBR) cable specification with a new VESA certified DP54 UHBR cable spec to enable up to four-lane UHBR13.5 link rate support (a maximum throughput of 54 Gbps) over a two-meter passive cable. As a result, the DisplayPort 2.1a update effectively doubles the passive cable length for UHBR13.5 GPU-to-display connections—which previously could only be supported through a DP80 UHBR cable—providing consumers with greater flexibility in their gaming or workstation setup.

Key Points: 
  • VESA also announces it has published a new Automotive Extension Services protocol specification for both DisplayPort 2.1a and the latest version of VESA's Embedded DisplayPort (eDP) specification, version 1.5a.
  • Silicon manufacturers are already adopting VESA's Automotive Extension Services protocol today for chipsets that will be integrated in future vehicles.
  • Most automotive displays currently use DisplayPort or eDP to carry video data from the central vehicle computer to the displays.
  • The VESA Automotive Extension Working Group, which is driving the new Automotive Extension specification protocol, is open to all VESA members.

Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries

Retrieved on: 
Thursday, November 30, 2023
Patient, Doctor of Pharmacy, IRB, ABA, Trevena, CNS, Burn, Severity, Prospective, Central nervous system, Safety, Oliceridine, Senior

Dr. Hill was independently responsible for the development and submission of the abstract.

Key Points: 
  • Dr. Hill was independently responsible for the development and submission of the abstract.
  • The single-center, prospective, case-controlled study was dual IRB approved and included 10 patients with burn injuries admitted between April and September 2023 and treated with OLINVYK.
  • Patients dosed with OLINVYK were compared to a matched historical control group (N=18) which included treatment across a range of other IV opioids.
  • “We look forward to the presentation of these data in the spring.”
    Financial support and study drug for the trial was provided by Trevena.

Malwarebytes Announces Free Vulnerability Assessment to Help IT Organizations Improve Security Posture Without Extra Costs

Retrieved on: 
Wednesday, December 6, 2023
Organization, Information security operations center, CVE, Risk, Blog, Common Vulnerability Scoring System, Security operations center, Social Security Trust Fund, National Security Advisor (India), Severity, Security, Health, IDC, Overalls, Environment, Risk management

SANTA CLARA, Calif., Dec. 6, 2023 /PRNewswire/ -- Malwarebytes, a global leader in real-time cyber protection, today announced its comprehensive vulnerability assessment module is now included in every ThreatDown bundle at no additional cost via its integrated console. Many IT organizations are struggling with rising cybersecurity costs associated with annual vendor price increases and the necessity of adding more tools to protect against an ever-increasing attack surface. Malwarebytes, with its portfolio of award-winning ThreatDown solutions, is taking a different approach, helping customers reduce threats, security complexity and costs by providing a free vulnerability assessment.

Key Points: 
  • Malwarebytes, with its portfolio of award-winning ThreatDown solutions, is taking a different approach, helping customers reduce threats, security complexity and costs by providing a free vulnerability assessment.
  • "Organizations need to prioritize prevention and strengthen their security posture, so they are less of an exploitable target," said Michael Suby, Research Vice President, Security & Trust, IDC.
  • Malwarebytes eliminates this conflict between security best practices and cost by pairing vulnerability assessment with its Security Advisor dashboard for free."
  • ThreatDown Vulnerability Assessment allows Malwarebytes customers to identify critical vulnerabilities and prioritize actions needed before open vulnerabilities can be exploited in a cyberattack.

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

Retrieved on: 
Thursday, November 2, 2023
Acute lymphoblastic leukemia, CRAC, T16, Asparaginase, LA, Society, Severity, ASH, Pancreatitis, TPN, AAP, St. Jude Children's Research Hospital, Patient, ALL, Parenteral nutrition, ICU, Pharmaceutical industry

LA JOLLA, Calif., Nov. 2, 2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, today announced that there will be a presentation of data from the initial cohort of the CRSPA study of Auxora™ (zegocractin) in asparaginase-induced pancreatic toxicity (AIPT) in a poster presentation at the 65th Annual American Society of Hematology (ASH) Meeting & Exposition being held December 9-12, 2023 in San Diego, CA.

Key Points: 
  • The presentation includes results from the first cohort consisting of nine patients from the CRSPA study.
  • ONCASPAR™ and RYLAYZE™), a nearly identical ALL treatment protocol as used in the CRSPA study.
  • Additionally, no CRSPA patients required total parenteral nutrition (TPN), compared to 68.8% in the historical matched control group.
  • Presentation Title: Zegocractin to Reduce the Severity of Asparaginase Associated Pancreatitis in Children with Acute Lymphoblastic Leukemia: Results of the Phase 1 Portion of the CRSPA Study

BrainCheck Expands First End-to-End Solution for Cognitive Care

Retrieved on: 
Tuesday, October 24, 2023
Summit Health, Alzheimer's disease, University of Washington School of Medicine, National Alzheimer's Project Act, Moca, Trial of the century, AD, Montreal Cognitive Assessment, Health information management, Medicare, Breast Cancer Awareness Month, Data, Deficit spending, D.O, Health, Research, Clinical trial, Dementia, Severity, Tablet, University, MSE, EHR, Patient, Computerize, Montreal, Cholesterol, Medical imaging, Medical device, MD, Index

AUSTIN, Texas, Oct. 24, 2023 /PRNewswire/ -- BrainCheck, Inc. launched the next generation of its comprehensive platform and unveiled its latest innovation, BrainCheck® Screen™, at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, Massachusetts from October 24-27, ahead of National Alzheimer's Awareness Month. New research supporting BrainCheck's comprehensive digital cognitive assessment tool will also be presented at the meeting.

Key Points: 
  • "More than six million Americans have Alzheimer's disease (AD), the most common type of dementia, but unfortunately many remain undiagnosed,i" said Kim Rodriguez, CEO of BrainCheck.
  • "Early diagnosis will help close this gap, and our platform empowers providers to easily access information on patients' cognitive health by offering a unique solution that includes screening, assessment, care planning, and monitoring.
  • The latest version brings cognitive care to the next level, expanding access to our technology from any device or location, in-clinic or remote.
  • The next generation of the BrainCheck platform allows digital cognitive testing on any internet-connected device – including phones, tablets and browsers – regardless of the patient or clinician's location.

Updated Clinical Trial Data Indicates Precision Oral Appliance Therapy with ProSomnus Devices is Non-Inferior to CPAP Therapy for the Treatment of Moderate to Severe Obstructive Sleep Apnea

Retrieved on: 
Wednesday, August 23, 2023
Severity, HNS, CPAP, Obstructive sleep apnea, STAR, OAT, Knokke-Heist, Sleep, Clinical trial, P4, First Line, Medicine, Congress, Patient, AHI, Observation, Entrepreneurship, FDA, Conference, Safety, Pharmaceutical industry

PLEASANTON, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), announced updated clinical trial data, presented at the ProSleep 2023 Users Conference earlier this month. The updated data indicate that the First Line Obstructive Sleep Apnea Treatment study (FLOSAT) is on track to achieve all endpoints.

Key Points: 
  • The updated data indicate that the First Line Obstructive Sleep Apnea Treatment study (FLOSAT) is on track to achieve all endpoints.
  • FLOSAT is an ongoing, prospective, independent, head-to-head study comparing the effectiveness of precision OAT as first-line treatment versus CPAP therapy.
  • In July , ProSomnus announced plans to design a head-to-head clinical trial comparing precision OAT and HNS in treating patients with severe OSA.
  • “The updated data and analysis from FLOSAT is validation that precision oral appliance therapy with ProSomnus devices is an effective front-line treatment for moderate to severe OSA,” said Len Liptak, Co-Founder and Chief Executive Officer of ProSomnus.

Educational Services & Consulting (ESC) Partners with Severe RPMS Adjuster Academy to Offer Top-Notch Post-License Training

Retrieved on: 
Tuesday, August 1, 2023
Severity, Insurance, Learning, Partnership, Student, Education, Education minister, Curriculum, ACA, Knowledge, ESC, Learning How to Learn, Management, Nursing

CLERMONT, Fla., Aug. 1, 2023 /PRNewswire-PRWeb/ -- Educational Services & Consulting (ESC), a leading provider of educational services in the accredited claims adjuster training sector, is thrilled to announce its partnership with Severe RPMS Adjuster Academy, a long-time leader in claims adjustment training and development. This strategic alliance aims to deliver comprehensive and cutting-edge claims adjustment training from pre-licensing to understanding the claims process, how to inspect and photo document interior and exterior damage, how to write a comprehensive estimate, how to process a supplement, and how to create reports and submit claims for review. Through the variety of online courses offered at Severe RPMS Adjuster Academy, claims adjusters will be empowered with the skills and knowledge required for success in their careers.

Key Points: 
  • CLERMONT, Fla., Aug. 1, 2023 /PRNewswire-PRWeb/ -- Educational Services & Consulting (ESC), a leading provider of educational services in the accredited claims adjuster training sector, is thrilled to announce its partnership with Severe RPMS Adjuster Academy, a long-time leader in claims adjustment training and development.
  • Through the variety of online courses offered at Severe RPMS Adjuster Academy, claims adjusters will be empowered with the skills and knowledge required for success in their careers.
  • Candidates seeking their ACA designation through ESC can continue their training through Severe RPMS Adjuster Academy once they receive their designation and state license.
  • For additional information about Severe RPMS Adjuster Academy and their range of ACA training programs, visit https://severerpmsadjusters.com/ .

Sodexo Q3 Fiscal 2023: solid organic revenue growth at +10.5%

Retrieved on: 
Friday, June 30, 2023
Food, Benefit, Foodservice, Sodexo, Workplace, Fishery, COVID-19, Seafood, National Space Facilities Control and Test Center, Natural Resources, LTIR, Comment, Webcast, CFO, Growth, FE, Severity, B2B, Safety, WWF, Pharmaceutical industry, Management, Holding company

As a result, third quarter Fiscal 2023 organic growth was +10.5%.

Key Points: 
  • As a result, third quarter Fiscal 2023 organic growth was +10.5%.
  • Revenue for the first nine months of Fiscal 2023, to the end of May, reached 18.1 billion euros, up +14.7%, or +12.4% organically.
  • Group organic revenue growth close to +11% and Group Underlying Operating Profit margin at 5.5%, at constant rates.
  • Sodexo will hold a conference call (in English) today at 9:00 a.m. (Paris time), 8:00 a.m. (London time) to comment on its Q3 Fiscal 2023 revenues.

FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata

Retrieved on: 
Friday, June 23, 2023
Research, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Janus, Yale School of Medicine, Inc., TEC, Diarrhea, Hepatocellular carcinoma, National Alopecia Areata Foundation, PFE, Aes, JAK3, Dermatology, ALLEGRO, Acne, Yale school, SALT, Hives, Associate, Rash, Alopecia areata, Hair, Patient, Autoimmune disease, Severity, Janus kinase 3, Headache, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, NYSE, Food, Pharmaceutical industry, Lancet, Pfizer

It is the first and only treatment approved by the FDA for adolescents (12+) with severe alopecia areata.

Key Points: 
  • It is the first and only treatment approved by the FDA for adolescents (12+) with severe alopecia areata.
  • “LITFULO is an important treatment advancement for alopecia areata, an autoimmune disease that previously had no FDA-approved options for adolescents and limited options available for adults,” said Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceuticals Business, Pfizer.
  • “With today’s approval, adolescents and adults who struggle with substantial hair loss have an opportunity to achieve significant scalp hair regrowth.”
    The FDA approval was based on results of clinical trials in alopecia areata.
  • “We believe the approval of LITFULO is a significant advancement for the treatment of alopecia areata, particularly for teens.